Katherine Ruffner
Keine laufenden Positionen mehr
Profil
Katherine L.
Ruffner worked as a Senior Director of Clinical Development at Seagen Inc. She was the Vice President of Clinical Development at CTI BioPharma Corp from 2008 to 2019.
Prior to that, she was an Assistant Professor at Vanderbilt University from 2002 to 2007.
She also worked as the Vice President of Clinical Development at ALX Oncology Holdings, Inc. from 2020 to 2021 and as the Chief Medical Officer at Cardiff Oncology, Inc. in 2021 to 2022.
Ruffner received her undergraduate degree from Duke University and her graduate degree from the University of Tennessee.
Ehemalige bekannte Positionen von Katherine Ruffner
| Unternehmen | Position | Ende |
|---|---|---|
| CARDIFF ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 22.04.2022 |
| ALX ONCOLOGY HOLDINGS INC. | Corporate Officer/Principal | 01.05.2021 |
| CTI BIOPHARMA CORP. | Chief Tech/Sci/R&D Officer | 01.02.2019 |
| Vanderbilt University | Corporate Officer/Principal | 01.01.2007 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Katherine Ruffner
| Duke University | Undergraduate Degree |
| University of Tennessee | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CARDIFF ONCOLOGY, INC. | Health Technology |
| ALX ONCOLOGY HOLDINGS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
